Auriga Reaffirms Buy Rating on Spectrum Pharma (SPPI)

By admin | 6 years ago

Spectrum Pharma (NASDAQ: SPPI)‘s stock had its “buy” rating restated by equities researchers at Auriga in a report issued on Thursday.

Shares of Spectrum Pharma opened at 11.35 on Thursday. Spectrum Pharma has a one year low of $6.94 and a one year high of $16.00. The company has a market cap of $670.5 million and a P/E ratio of 8.33.

Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Spectrum Pharma in a research note to investors on Friday, March 2nd.

Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology.

About the author